Feedback / Questions
Lovaxin B (OST-HER2) - OS Therapies
https://www.businesswire.com/news/home/20250624414411/en/OS-Therapies-Receives-Positive-FDA-Meeting-Feedback-on-Regulatory-Pathway-for-Accelerated-Approval-of-OST-HER2-in-the-Prevention-or-Delay-of-Recurrent-Fully-Resected-Pediatric-Lung-Metastatic-Osteosarcoma
Jun 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next